A kind of traditional Chinese medicine composition for treating chronic renal failure

Abstract

The invention discloses a traditional Chinese medicine composition for treating chronic renal failure. The raw material comprises the following parts by weight: 25-35 parts of Allium, 1-5 parts of Cordyceps sinensis, 25-35 parts of Astragalus, 10-20 parts of Angelica, 15-25 parts of fairy spleen, 15-25 parts of Eucommia, 10-20 parts of Chinese yam , 10-20 parts of Atractylodes macrocephala, 5-15 parts of turtle shell, 10-20 parts of Moutan bark, 5-15 parts of cassia twig, 10-15 parts of rhubarb, 25-35 parts of Poria cocos, 10-20 parts of Alisma, 10-20 parts 15-25 parts of Polyporus, 15‑25 parts of Sichuan Achyranthes bidentata. Allium scallion is the king drug, and it was accidentally discovered that it has the effect of promoting yang and diuresis. The compatibility of the prescription can significantly improve the patient's clinical symptoms. The patient's edema subsides significantly, and the urine output increases. It has few side effects and low cost, can improve the quality of life of patients, and is beneficial to clinical popularization and application.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating chronic renal failure. Background technique [0002] The concept of chronic renal failure in Western medicine refers to various causes acting on the kidneys, resulting in chronic progressive and irreversible damage to the nephrons, making them unable to maintain basic functions. Clinically, the retention of metabolites and toxins, water, electrolytes, acid A series of clinical syndromes characterized by disturbances of alkali balance and certain endocrine dysfunctions. The clinical staging standard of chronic renal failure is: 1. Renal insufficiency compensation stage (Ccr80-50ml / min, Scr133-177μmol / L), 2. Renal insufficiency decompensation stage (Ccr50-20ml / min, Scr178- 442μmol / L), 3. renal failure stage (Ccr20-10ml / min, Scr443-707μmol / L), 4. uremia stage (Ccr<10ml / min, Scr>707μmol / L...

AI Technical Summary

Problems solved by technology

These treatments are aimed at "renal protection", but they can only control the risk factors of chronic renal failure developing into uremia. In addition, when the blood creatinine and blood potassium are at high levels, angiotensin converting enzyme inhibitors, angiotensin receptor antagonist

However, the replacement therapy hemodialysis, peritoneal dialysis, and kidney transplantation are complicated in technology, the quality of life of patients is reduced, the cost is high, the pressure of medical insurance funds is high, and kidney sources are difficult to find, which increases the difficulty of widespread clinical application.

[0004] In conclusion, the clinical manifestations of chronic renal failure are complex, its pathogenesis and various factors influence each other, and the treatment is difficult, especially in the medical treatment, there is still no breakthrough, and the prognosis is poor

At present, the early treatment of this disease is mainly through reasonable diet control and intestinal detoxification to delay the progression of the disease. If the treatment is in the middle to late stage, dialysis or kidney transplantation is required to alleviate the disease, which makes the quality of life of the patient decline rapidly. And it is difficult to implement in grass-roots hospitals, which is not conducive to improving the overall health guarantee of the broad masses of the people

Images